Peter Traber Biography and Net Worth

Dr. Peter G. Traber M.D. serves as Independent Director of the Company. Dr. Traber joined the Caladrius Board in January 2015. He has extensive experience in medicine, science and the pharmaceutical industry. Since July 2018 he has served as Partner to Alacrita Consulting. From March 2011 until June 2018, he was President and Chief Executive Officer of Galectin Therapeutics, Inc. (Nasdaq: GALT), where he served since 2010 as Chief Medical Officer and starting in 2009 as a member of its Board of Directors. Galectin is a publicly traded biotechnology company that is developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. Since 2008, he has been President Emeritus of Baylor College of Medicine, where he was Chief Executive Officer from 2003 to 2008. Dr. Traber also has extensive big pharma leadership experience, serving from 2000 to 2003 as Senior Vice President of clinical development and medical affairs and Chief Medical Officer of GlaxoSmithKline. He has also served as CEO of the University of Pennsylvania Health System, and as Chair of the Department of Internal Medicine, and Chief of Gastroenterology for the University of Pennsylvania School of Medicine. Dr. Traber has managed a molecular biology research laboratory and published more than 100 research articles, reviews, and book chapters. He received his M.D. from Wayne State School of Medicine, a B.S. in chemical engineering from the University of Michigan, and a certificate in medical leadership from Wharton Business School.

What is Peter G. Traber's net worth?: The estimated net worth of Peter G. Traber is at least $0.00 as of September 25th, 2023. Dr. Traber owns 451,826 shares of Selecta Biosciences stock worth more than $0 as of April 19th. This net worth evaluation does not reflect any other assets that Dr. Traber may own. Additionally, Dr. Traber receives an annual salary of $670,290.00 as Insider at Selecta Biosciences. Learn More about Peter G. Traber's net worth.
How old is Peter G. Traber?: Dr. Traber is currently 68 years old. There are 5 older executives and no younger executives at Selecta Biosciences. Learn More on Peter G. Traber's age.
What is Peter G. Traber's salary?: As the Insider of Selecta Biosciences, Inc., Dr. Traber earns $670,290.00 per year. The highest earning executive at Selecta Biosciences is Dr. Carsten Brunn Ph.D., CEO, President & Director, who commands a salary of $914,660.00 per year. Learn More on Peter G. Traber's salary.
How do I contact Peter G. Traber?: The corporate mailing address for Dr. Traber and other Selecta Biosciences executives is 65 Grove Street, Watertown MA, 02472. Selecta Biosciences can also be reached via phone at (617) 923-1400 and via email at [email protected]. Learn More on Peter G. Traber's contact information.
Has Peter G. Traber been buying or selling shares of Selecta Biosciences?: Peter G. Traber has not been actively trading shares of Selecta Biosciences in the last ninety days. Most recently, Peter G. Traber sold 705 shares of the business's stock in a transaction on Monday, September 25th. The shares were sold at an average price of $1.06, for a transaction totalling $747.30. Following the completion of the sale, the insider now directly owns 451,826 shares of the company's stock, valued at $478,935.56. Learn More on Peter G. Traber's trading history.
Who are Selecta Biosciences' active insiders?: Selecta Biosciences' insider roster includes Timothy Barabe (Director), Carsten Brunn (CEO), Nishan de Silva (Director), Timothy Springer (Director), Kevin Tan (CFO), and Peter Traber (Insider). Learn More on Selecta Biosciences' active insiders.
Are insiders buying or selling shares of Selecta Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 3,637 shares worth more than $3,855.22. The most recent insider tranaction occured on September, 25th when CEO Carsten Brunn sold 2,932 shares worth more than $3,107.92. Insiders at Selecta Biosciences own 31.2% of the company. Learn More about insider trades at Selecta Biosciences.
Information on this page was last updated on 9/25/2023.

Peter G. Traber Insider Trading History at Selecta Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/25/2023	Sell	705	$1.06	$747.30	451,826
1/5/2022	Sell	3,226	$3.09	$9,968.34
12/10/2021	Sell	4,083	$2.99	$12,208.17
10/13/2021	Sell	3,636	$4.39	$15,962.04
5/26/2021	Buy	20,000	$3.99	$79,800.00	135,500
5/24/2021	Buy	12,500	$3.32	$41,500.00	110,500
3/17/2021	Buy	10,000	$4.53	$45,300.00	88,000
12/14/2020	Buy	40,000	$3.24	$129,600.00	40,000

Peter G. Traber Buying and Selling Activity at Selecta Biosciences

Selecta Biosciences Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $1.06

$0.88

$1.26

2 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

Peter Traber Biography and Net Worth

What is Peter G. Traber's net worth?

How old is Peter G. Traber?

What is Peter G. Traber's salary?

How do I contact Peter G. Traber?

Has Peter G. Traber been buying or selling shares of Selecta Biosciences?

Who are Selecta Biosciences' active insiders?

Are insiders buying or selling shares of Selecta Biosciences?